Enasidenib Induces Molecular Remissions in IDH2-Mutated, Relapsed/Refractory AML
A first-in-human trial of patients with relapsed and/or refractory, IDH2-mutated acute myeloid leukemia (AML) found that the IDH2 inhibitor enasidenib was an effective salvage...
Ravulizumab: A New Complement Inhibitor for Patients With Paroxysmal Nocturnal Hemoglobinuria
Ravulizumab was noninferior to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who had never received treatment with complement inhibitors, according to findings from...
Can a Selinexor Combination STOMP Out Relapsed/Refractory Multiple Myeloma?
The combination of selinexor plus low-dose bortezomib and dexamethasone produced high response rates in patients with relapsed or refractory multiple myeloma (MM), with a...
Duvelisib Bests Ofatumumab in Relapsed and Refractory CLL/SLL
In the phase III DUO trial, treatment with the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib improved progression-free survival (PFS) and overall response, compared...
Preventing Hepatitis B Virus Reactivation During Immunochemotherapy for Lymphoma
Administering prophylactic antiviral treatment is effective in preventing hepatitis B virus (HBV) reactivation in patients with B-cell non-Hodgkin lymphoma (NHL) being treated with an...
Do Children With CVC-Related Thromboses Need Anticoagulation Treatment?
Results from a prospective study of children who were hospitalized in a pediatric intensive care unit (PICU) revealed that the incidence of central vein...
No Benefit With Adding Eltrombopag to Azacitidine in Patients With Higher-Risk MDS
In the phase III SUPPORT trial, researchers tested the hypothesis that concomitant administration of the thrombopoietin receptor agonist eltrombopag could ameliorate the thrombocytopenic effects...
Early-Phase Trial Shows Venetoclax Plus HMA Has High Response Rates in Older Patients With...
In a phase Ib dose-escalation and dose-expansion study published in Blood, two-thirds of older patients with acute myeloid leukemia (AML) responded to the combination...
Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis
Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...
Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP
Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...
Current Issue
January 2019 Annual Meeting Edition
This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.
